AstraZeneca Covid Vaccine Linked To Rare Neurological Disord
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Eleven people who received the AstraZeneca-Oxford Covid-19 vaccine have developed a rare neurological disorder called Guillain-Barre syndrome, clinicians in India and England have reported in two separate studies.

While seven cases were reported from a medical centre in Kerala, where about 1.2 million people were administered the AstraZeneca Covid-19 vaccine, known as Covishield in India, four were reported from Nottingham, UK, in an area in which approximately 7 lakh people received the jab. All 11 had received the Covid preventive 10-22 days earlier.

The two studies, describe an unusual variant of GBR characterised by prominent facial weakness. The frequency of GBS from the areas where the cases were reported was estimated to be up to 10 times greater than expected, the authors of the two studies said.

As of April 22, 2021, around 1.5 million individuals in three districts of Kerala, had been vaccinated with Covid-19 vaccines, the researchers noted, adding that over 80 percent of these individuals (1.2 million) received the AstraZeneca preventive. In this population, during the period from mid-March to mid-April 2021, the researchers from Aster Medcity, Kochi, and Indo-American Brain and Spine Center, Vaikom, Kerala, observed seven cases of GBS that occurred within two weeks of the first dose of vaccination.

All seven patients developed severe GBS, the researchers said. The frequency of GBS was 1.4 to 10-fold higher than that expected in this period for a population of this magnitude, they said.

Dr. T●●●●z H●●●●●●i and 1 others like this11 shares